VIRX vs. DRRX, XCUR, NAII, GDTC, IBIO, CTXR, LSB, LIAN, LGVN, and ATHE
Should you be buying Viracta Therapeutics stock or one of its competitors? The main competitors of Viracta Therapeutics include DURECT (DRRX), Exicure (XCUR), Natural Alternatives International (NAII), CytoMed Therapeutics (GDTC), iBio (IBIO), Citius Pharmaceuticals (CTXR), Lakeshore Biopharma (LSB), LianBio (LIAN), Longeveron (LGVN), and Alterity Therapeutics (ATHE). These companies are all part of the "pharmaceutical products" industry.
Viracta Therapeutics vs.
DURECT (NASDAQ:DRRX) and Viracta Therapeutics (NASDAQ:VIRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.
In the previous week, DURECT had 3 more articles in the media than Viracta Therapeutics. MarketBeat recorded 6 mentions for DURECT and 3 mentions for Viracta Therapeutics. Viracta Therapeutics' average media sentiment score of 0.58 beat DURECT's score of 0.55 indicating that Viracta Therapeutics is being referred to more favorably in the news media.
DURECT presently has a consensus price target of $5.00, suggesting a potential upside of 521.20%. Viracta Therapeutics has a consensus price target of $4.05, suggesting a potential upside of 2,509.54%. Given Viracta Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viracta Therapeutics is more favorable than DURECT.
DURECT received 287 more outperform votes than Viracta Therapeutics when rated by MarketBeat users. However, 70.73% of users gave Viracta Therapeutics an outperform vote while only 62.70% of users gave DURECT an outperform vote.
DURECT has higher revenue and earnings than Viracta Therapeutics. DURECT is trading at a lower price-to-earnings ratio than Viracta Therapeutics, indicating that it is currently the more affordable of the two stocks.
Viracta Therapeutics has a net margin of 0.00% compared to DURECT's net margin of -198.58%. DURECT's return on equity of -300.62% beat Viracta Therapeutics' return on equity.
DURECT has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, Viracta Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.
28.0% of DURECT shares are held by institutional investors. Comparatively, 31.4% of Viracta Therapeutics shares are held by institutional investors. 3.2% of DURECT shares are held by company insiders. Comparatively, 10.7% of Viracta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Viracta Therapeutics beats DURECT on 9 of the 17 factors compared between the two stocks.
Get Viracta Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viracta Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VIRX) was last updated on 1/30/2025 by MarketBeat.com Staff
Free VIRX Stock Alerts